These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 37148547

  • 1. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
    Chung CT, Lakhani I, Chou OHI, Lee TTL, Dee EC, Ng K, Wong WT, Liu T, Lee S, Zhang Q, Cheung BMY, Tse G, Zhou J.
    Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q.
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [Abstract] [Full Text] [Related]

  • 3. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X, Zhang N, Lu L, Gao T, Chou OHI, Wong WT, Chang C, Wai AKC, Lip GYH, Zhang Q, Tse G, Liu T, Zhou J.
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb 23; 10(2):103-117. PubMed ID: 37962962
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI, Ning J, Chan RNC, Chung CT, Huang H, Ng K, Dee EC, Lee S, Kaewdech A, Chow AKM, Man NK, Liu T, Jing F, Cheung BMY, Tse G, Zhou J.
    J Natl Compr Canc Netw; 2024 Jun 23; 22(2 D):. PubMed ID: 38862004
    [Abstract] [Full Text] [Related]

  • 10. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, Sing CW, Cheung CL.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2251177. PubMed ID: 36648944
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
    Mui JV, Zhou J, Lee S, Leung KSK, Lee TTL, Chou OHI, Tsang SL, Wai AKC, Liu T, Wong WT, Chang C, Tse G, Zhang Q.
    Front Cardiovasc Med; 2021 Jan 03; 8():747620. PubMed ID: 34746262
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
    Lee HF, Chan YH, Chuang C, Li PR, Yeh YH, Hsiao FC, Peng JR, See LC.
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun 02; 9(4):301-310. PubMed ID: 36639127
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM.
    Sci Rep; 2018 Mar 13; 8(1):4466. PubMed ID: 29535389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.